A recent federal court ruling has vacated HRSA’s long-standing 2013 GPO policy, raising new questions about how 340B hospitals can approach initial drug inventory purchases.
A recent court ruling is reshaping how hospitals should approach 340B eligibility—particularly for off-site locations. For years, many have assumed that registration in OPAIS was
In early March 2026, a federal district court issued a significant ruling in Albany Med Health System v. HRSA, challenging long-standing assumptions about when hospital child
Virtue 340B partners with HANYS Marketplace to support hospital leaders with independent 340B compliance insight and oversight clarity Virtue 340B® has partnered with HANYS Marketplace®, a
At GCA340B, staying ahead of the compliance curve isn’t just a priority—it’s the promise we make to every Covered Entity we serve. Compliance and auditing are
The 340B Drug Pricing Program is vital for safety-net healthcare providers, allowing them to enhance access to medications, reduce medication costs for vulnerable populations, and
January 1, 2026, marks a significant shift, as the Inflation Reduction Act (IRA)-driven Maximum Fair Price (MFP) pricing and the 340B Rebate Model Pilot Program
We’re excited to share that Katy’s 340B Compass — our educational video series designed to help covered entities and 340B stakeholders navigate compliance with clarity
Virtue 340B is an independent 340B compliance and audit firm dedicated to helping healthcare organizations administer their 340B programs with transparency, integrity, and confidence. We
Virtue 340B is an independent 340B compliance and audit firm dedicated to helping healthcare organizations administer their 340B programs with transparency, integrity, and confidence. We
